Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model

Blood

Volumn 103, Issue 4, 2004, Pages 1261-1269

  Berger, Carolina ^b   Blau, C Anthony ^b   Huang, Meei Li ^b   Iuliucci, John D ^b   Dalgarno, David C ^b   Gaschet, Joëlle ^b   Heimfeld, Shelly ^b   Clackson, Tim ^b   Riddell, Stanley R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AP 1903; CELL RECEPTOR; FAS ANTIGEN; FAS RECEPTOR; GENE PRODUCT; UNCLASSIFIED DRUG;

ADOLESCENT; ADOPTIVE TRANSFER; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; DIMERIZATION; DRUG RESISTANCE; DRUG SENSITIVITY; EPITOPE MAPPING; GENE EXPRESSION; GENETIC TRANSDUCTION; IMMUNE RESPONSE; MACACA; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; REGULATORY MECHANISM; SUICIDE GENE; T LYMPHOCYTE; TRANSGENE;

EID: 0842264038     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2908     Document Type: Article

References (65)

1. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:570-578.
2. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
3. + T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science. 1996;272:1939-1943.
4. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med. 2002;8:47-53.
5. Brentjens RJ, Latouche J-B, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279-286.
6. Sadelain M, Rivière I, Brentjens RJ. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35-45.
7. Byrne JA, Oldstone MBA. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. J Immunol. 1986;136:698-704.
8. Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med. 2000;192:1637-1643.
9. Kolb H-J, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
10. Collins Jr RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
11. Van den Eynde BJ, Van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol. 1997;9:684-693.
12. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10:673-679.
13. Gilboa E. The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol. 2002;2:789-792.
14. Heyman RA, Borrelli E, Lesley J, et al. Thymidine kinase obliteration: creation of transgenic mice controlled immune deficiency. Proc Natl Acad Sci U S A. 1989;86:2698-2702.
15. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 1994;54:1503-1506.
16. Lal S, Lauer UM, Niethammer D, Beck JF, Schlegel PG. Suicide genes: past, present and future perspectives. Immunol Today. 2000;21:48-54.
17. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719-1724.
18. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2:216-223.
19. Berger C, Huang M-L, Gough M, et al. Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol. 2001;75:799-808.
20. Lutzko C, Kruth S, Abrams-Ogg ACG, et al. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine α-L-iduronidase deficiency. Blood. 1999;93:1895-1905.
21. + hematopoietic cells. Blood. 2001;97:1951-1959.
22. Ciceri F, Bonini C, Marktel S, et al. Long term follow-up in 30 patients receiving HSV-TK transduced donor lymphocytes after allo-BMT [abstract]. Blood. 1999;94:668a.
23. Introna M, Barbui AM, Bambacioni F, et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther. 2000;11:611-620.
24. Deans JP, Kalt L, Ledbetter JA, et al. Association of 76/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. J Biol Chem. 1995;270:22632-22638.
25. Golay JT, Clark EA, Beverley PCL. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol. 1985;135:3795-3801.
26. Takami A, Saito M, Nakao S, et al. CD20-positive T-cell chronic lymphocytic leukemia. Br J Haematol. 1998;102:1327-1329.
27. Maloney D, Liles T, Czerwinski D, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84:2457-2466.
28. Spencer DM, Belshaw PJ, Chen L, et al. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Curr Biol. 1996;6:839-847.
29. Clackson T, Yang W, Rozamus LW, et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. 1998;95:10437-10442.
30. Thomis DC, Marktel S, Bonini C, et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood. 2001;97:1249-1257.
31. Berger C, Blau CA, Clackson T, Riddell SR, Heimfeld S. CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. Blood. 2003;101:476-484.
32. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther. 1996;7:1405-1413.
33. Iuliucci JD, Oliver SD, Morley S, et al. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol. 2001;41:870-879.
34. Parham P, Sehgal PK, Brodsky FM. Anti-HLA-A, B, C monoclonal antibodies with no alloantigenic specificity in humans define polymorphisms in other primate species. Nature. 1979;279:639-641.
35. Rosenberg YJ, Janossy G. The importance of lymphocyte trafficking in regulating blood lymphocyte levels during HIV and SIV infections. Semin Immunol. 1999;11:139-154.
36. Osada N, Hida M, Kususda J, et al. Assignment of 118 novel cDNAs of cynomolgus monkey brain to human chromosomes. Gene. 2001;275:31-37.
37. Li Z, Düllmann J, Schiedlmeier B, et al. Murine leukemia induced by retroviral gene marking. Science. 2002;296:497.
38. Baum C, Düllmann J, Li Z, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 2003;101:2099-2114.
39. Hantzopoulos PA, Chitra S, Glass DJ, Goldfarb MP, Yancopoulos GD. The low affinity NGF receptor, p75, can collaborate with each of the Trks to potentiate functional responses to the neurotrophins. Neuron. 1994;13:187-201.
40. Agarwal M, Austin TW, Morel F, et al. Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J Virol. 1998;72:3720-3728.
41. Bonini S, Lambiase A, Bonini S, et al. Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. Proc Natl Acad Sci U S A. 1996;93:10955-10960.
42. Thorpe LW, Perez-Polo JR. The influence of nerve growth factor on the in vitro proliferation response of rat spleen lymphocytes. J Neurosci Res. 1987;18:134-139.
43. Otten U, Ehrhard P, Peck R. Nerve growth factor induces growth and differentiation of human B lymphocytes. Proc Natl Acad Sci U S A. 1989;86:10059-10063.
44. Spencer DM. Developments in suicide genes for preclinical and clinical applications. Curr Opin Mol Ther. 2000;2:433-440.
45. Jin L, Siritanaratkul N, Emery DW, et al. Targeted expansion of genetically modified bone marrow cells. Proc Natl Acad Sci U S A. 1998;95:8093-8097.
46. Jin L, Zeng H, Chien S, et al. In vivo selection using a cell-growth switch. Nat Genet. 2000;26:64-66.
47. Quinn ER, Lum LG, Trevor KT. T cell activation modulates retrovirus-mediated gene expression. Hum Gene Ther. 1998;9:1457-1467.
48. + T lymphocytes: green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nat Med. 1999;5:843-847.
49. Flügel A, Berkowicz T, Ritter T, et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity. 2001;14:547-560.
50. Hammer MH, Flügel A, Seifert M, et al. Potential of allospecific gene-engineered T cells in transplantation gene therapy: specific T cell activation determines transgene expression in vitro and in vivo. Hum Gene Ther. 2000;11:1303-1311.
51. Jacob J, Baltimore D. Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature. 1999;399:593-597.
52. Jenuwein T, Forrester WG, Fernández-Herrero LA, et al. Extension of chromatin accessibility by nuclear matrix attachment regions. Nature. 1997;385:269-272.
53. Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001;97:63-72.
54. Maury S, Salomon B, Klatzmann D, Cohen JL. Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice. Blood. 2001;98:3156-3158.
55. Litvinova E, Maury S, Boyer O, et al. Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. Blood. 2002;100:2020-2025.
56. Lee FS, Kim AH, Khursigara G, Chao MV. The uniqueness of being a neurotrophin receptor. Curr Opin Neurobiol. 2001;11:281-286,
57. Bonini C, Grez M, Traversari C, et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med. 2003;9:367-369.
58. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, Le Deist F. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255-256.
59. Lenardo M, Chan FK-M, Hornung F, et al. Mature lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rey Immunol. 1999;17:221-253.
60. Plas DR, Rathmell JC, Thompson CB. Homeostatic control of lymphocyte survival: potential origins and implications. Nat Immunol. 2002;3:515-521.
61. L. Immunity. 1995;3:87-98.
62. Irmler M, Thorne M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-195.
63. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388:300-304.
64. Fan L, Freeman KW, Khan T, Pham E, Spencer DM. Improved artificial death switches based on caspases and FADD. Hum Gene Ther. 1999;10:2273-2285.
65. MacCorkle RA, Freeman KW, Spencer DM. Synthetic activation of caspases: artificial death switches. Proc Natl Acad Sci U S A. 1998;95:3655-3660.